Advertisement

Progress in Allosteric Database

  • Kun Song
  • Jian Zhang
  • Shaoyong Lu
Chapter
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 1163)

Abstract

An allosteric mechanism refers to the biological regulation process wherein macromolecules propagate the effect of ligand binding at one site to a spatially distant orthosteric locus, thus affecting activity. The theory has remained a trending topic in biology research for over 50 years, since the understanding of allostery is fundamental for gleaning numerous biological processes and developing new drug therapies. In the past two decades, the allosteric paradigm has evolved into more descriptive models, with ever-expanding amounts of experimental data pertaining to newly identified allosteric molecules. The AlloSteric Database (ASD, accessible at http://mdl.shsmu.edu.cn/ASD), which is a comprehensive knowledge repository, has provided the public with integrated information encompassing allosteric proteins, modulators, sites, pathways, and networks to investigate allostery since 2009. In this chapter, we introduce the history and usage of the ASD and give attention to specific applications that have benefited from the ASD.

Keywords

ASD Allostery Drug development 

References

  1. 1.
    Alexandrov V, Lehnert U, Echols N, Milburn D, Engelman D, Gerstein M (2005) Normal modes for predicting protein motions: a comprehensive database assessment and associated Web tool. Protein Sci 14(3):633–643PubMedPubMedCentralCrossRefGoogle Scholar
  2. 2.
    Armstrong N, Gouaux E (2000) Mechanisms for activation and antagonism of an AMPA-sensitive glutamate receptor: crystal structures of the GluR2 ligand binding core. Neuron 28(1):165–181PubMedCrossRefPubMedCentralGoogle Scholar
  3. 3.
    Bian Y, Feng Z, Yang P, Xie XQ (2017) Integrated in silico fragment-based drug design: case study with allosteric modulators on metabotropic glutamate receptor 5. AAPS J 19(4):1235–1248PubMedPubMedCentralCrossRefGoogle Scholar
  4. 4.
    Changeux JP, Christopoulos A (2016) Allosteric modulation as a unifying mechanism for receptor function and regulation. Cell 166(5):1084–1102PubMedCrossRefPubMedCentralGoogle Scholar
  5. 5.
    Changeux JP, Edelstein SJ (2005) Allosteric mechanisms of signal transduction. Science 308(5727):1424–1428PubMedCrossRefPubMedCentralGoogle Scholar
  6. 6.
    Chessari G, Woodhead AJ (2009) From fragment to clinical candidate–a historical perspective. Drug Discov Today 14(13–14):668–675PubMedCrossRefPubMedCentralGoogle Scholar
  7. 7.
    Congreve M, Oswald C, Marshall FH (2017) Applying structure-based drug design approaches to allosteric modulators of GPCRs. Trends Pharmacol Sci 38(9):837–847PubMedCrossRefPubMedCentralGoogle Scholar
  8. 8.
    Conn PJ, Pin JP (1997) Pharmacology and functions of metabotropic glutamate receptors. Annu Rev Pharmacol Toxicol 37:205–237PubMedPubMedCentralCrossRefGoogle Scholar
  9. 9.
    Cuff AL, Sillitoe I, Lewis T, Redfern OC, Garratt R, Thornton J, Orengo CA (2009) The CATH classification revisited–architectures reviewed and new ways to characterize structural divergence in superfamilies. Nucleic Acids Res 37(Database issue):D310–D314PubMedCrossRefPubMedCentralGoogle Scholar
  10. 10.
    Davis M, Tobi D (2014) Multiple Gaussian network modes alignment reveals dynamically variable regions: the hemoglobin case. Proteins 82(9):2097–2105PubMedCrossRefPubMedCentralGoogle Scholar
  11. 11.
    de Kloe GE, Bailey D, Leurs R, de Esch IJ (2009) Transforming fragments into candidates: small becomes big in medicinal chemistry. Drug Discov Today 14(13–14):630–646PubMedCrossRefPubMedCentralGoogle Scholar
  12. 12.
    Dokholyan NV (2016) Controlling allosteric networks in proteins. Chem Rev 116(11):6463–6487PubMedCrossRefPubMedCentralGoogle Scholar
  13. 13.
    Erman B (2006) The gaussian network model: precise prediction of residue fluctuations and application to binding problems. Biophys J 91(10):3589–3599PubMedPubMedCentralCrossRefGoogle Scholar
  14. 14.
    Feher VA, Durrant JD, Van Wart AT, Amaro RE (2014) Computational approaches to mapping allosteric pathways. Curr Opin Struct Biol 25:98–103PubMedCrossRefPubMedCentralGoogle Scholar
  15. 15.
    Fischer S, Olsen KW, Nam K, Karplus M (2011) Unsuspected pathway of the allosteric transition in hemoglobin. Proc Natl Acad Sci U S A 108(14):5608–5613PubMedPubMedCentralCrossRefGoogle Scholar
  16. 16.
    Goodey NM, Benkovic SJ (2008) Allosteric regulation and catalysis emerge via a common route. Nat Chem Biol 4(8):474–482PubMedCrossRefPubMedCentralGoogle Scholar
  17. 17.
    Gregory KJ, Dong EN, Meiler J, Conn PJ (2011) Allosteric modulation of metabotropic glutamate receptors: structural insights and therapeutic potential. Neuropharmacology 60(1):66–81PubMedCrossRefPubMedCentralGoogle Scholar
  18. 18.
    Huang Z, Zhu L, Cao Y, Wu G, Liu X, Chen Y, Wang Q, Shi T, Zhao Y, Wang Y, Li W, Li Y, Chen H, Chen G, Zhang J (2011) ASD: a comprehensive database of allosteric proteins and modulators. Nucleic Acids Res 39(Database issue):D663–D669PubMedCrossRefPubMedCentralGoogle Scholar
  19. 19.
    Huang Z, Mou L, Shen Q, Lu S, Li C, Liu X, Wang G, Li S, Geng L, Liu Y, Wu J, Chen G, Zhang J (2014) ASD v2.0: updated content and novel features focusing on allosteric regulation. Nucleic Acids Res 42(Database issue):D510–D516PubMedCrossRefPubMedCentralGoogle Scholar
  20. 20.
    Huang M, Song K, Liu X, Lu S, Shen Q, Wang R, Gao J, Hong Y, Li Q, Ni D, Xu J, Chen G, Zhang J (2018) AlloFinder: a strategy for allosteric modulator discovery and allosterome analyses. Nucleic Acids Res 46(W1):W451–W458PubMedPubMedCentralCrossRefGoogle Scholar
  21. 21.
    Jiang L, Zhang X, Chen X, He Y, Qiao L, Zhang Y, Li G, Xiang Y (2015) Virtual screening and molecular dynamics study of potential negative allosteric modulators of mGluR1 from Chinese herbs. Molecules 20(7):12769–12786PubMedPubMedCentralCrossRefGoogle Scholar
  22. 22.
    Johnstone S, Albert JS (2017) Pharmacological property optimization for allosteric ligands: a medicinal chemistry perspective. Bioorg Med Chem Lett 27(11):2239–2258PubMedCrossRefPubMedCentralGoogle Scholar
  23. 23.
    Joseph-McCarthy D, Campbell AJ, Kern G, Moustakas D (2014) Fragment-based lead discovery and design. J Chem Inf Model 54(3):693–704.  https://doi.org/10.1021/ci400731wCrossRefPubMedPubMedCentralGoogle Scholar
  24. 24.
    Kew JN, Kemp JA (2005) Ionotropic and metabotropic glutamate receptor structure and pharmacology. Psychopharmacology 179(1):4–29PubMedCrossRefPubMedCentralGoogle Scholar
  25. 25.
    Koshland DE Jr, Nemethy G, Filmer D (1966) Comparison of experimental binding data and theoretical models in proteins containing subunits. Biochemistry 5(1):365–385PubMedCrossRefPubMedCentralGoogle Scholar
  26. 26.
    Kumar A, Voet A, Zhang KY (2012) Fragment based drug design: from experimental to computational approaches. Curr Med Chem 19(30):5128–5147PubMedCrossRefPubMedCentralGoogle Scholar
  27. 27.
    Leach AR, Gillet VJ, Lewis RA, Taylor R (2010) Three-dimensional pharmacophore methods in drug discovery. J Med Chem 53(2):539–558PubMedCrossRefPubMedCentralGoogle Scholar
  28. 28.
    Li H, Chang YY, Yang LW, Bahar I (2016) iGNM 2.0: the Gaussian network model database for biomolecular structural dynamics. Nucleic Acids Res 44(D1):D415–D422PubMedCrossRefPubMedCentralGoogle Scholar
  29. 29.
    Lindsley CW, Emmitte KA, Hopkins CR, Bridges TM, Gregory KJ, Niswender CM, Conn PJ (2016) Practical strategies and concepts in GPCR allosteric modulator discovery: recent advances with metabotropic glutamate receptors. Chem Rev 116(11):6707–6741PubMedPubMedCentralCrossRefGoogle Scholar
  30. 30.
    Liu Y, Bahar I (2010) Toward understanding allosteric signaling mechanisms in the ATPase domain of molecular chaperones. Pac Symp Biocomput 2010:269–280Google Scholar
  31. 31.
    Lu S, Zhang J (2018) Small molecule allosteric modulators of G-protein-coupled receptors: drug-target interactions. J Med Chem 62(1):24–45.  https://doi.org/10.1021/acs.jmedchem.7b01844CrossRefPubMedPubMedCentralGoogle Scholar
  32. 32.
    Lu S, Huang W, Zhang J (2014a) Recent computational advances in the identification of allosteric sites in proteins. Drug Discov Today 19(10):1595–1600PubMedCrossRefPubMedCentralGoogle Scholar
  33. 33.
    Lu S, Li S, Zhang J (2014b) Harnessing allostery: a novel approach to drug discovery. Med Res Rev 34(6):1242–1285PubMedCrossRefPubMedCentralGoogle Scholar
  34. 34.
    Lu S, Jang H, Muratcioglu S, Gursoy A, Keskin O, Nussinov R, Zhang J (2016) Ras conformational ensembles, allostery, and signaling. Chem Rev 116(11):6607–6665PubMedCrossRefPubMedCentralGoogle Scholar
  35. 35.
    Monod J, Wyman J, Changeux JP (1965) On the nature of allosteric transitions: a plausible model. J Mol Biol 12:88–118PubMedCrossRefPubMedCentralGoogle Scholar
  36. 36.
    Motlagh HN, Wrabl JO, Li J, Hilser VJ (2014) The ensemble nature of allostery. Nature 508(7496):331–339PubMedPubMedCentralCrossRefGoogle Scholar
  37. 37.
    Murray CW, Rees DC (2009) The rise of fragment-based drug discovery. Nat Chem 1(3):187–192PubMedCrossRefGoogle Scholar
  38. 38.
    Murzin AG, Brenner SE, Hubbard T, Chothia C (1995) SCOP: a structural classification of proteins database for the investigation of sequences and structures. J Mol Biol 247(4):536–540PubMedPubMedCentralGoogle Scholar
  39. 39.
    Nussinov R (2016) Introduction to protein ensembles and allostery. Chem Rev 116(11):6263–6266PubMedCrossRefPubMedCentralGoogle Scholar
  40. 40.
    Nussinov R, Tsai CJ (2013) Allostery in disease and in drug discovery. Cell 153(2):293–305PubMedCrossRefPubMedCentralGoogle Scholar
  41. 41.
    Nussinov R, Tsai CJ (2014) Unraveling structural mechanisms of allosteric drug action. Trends Pharmacol Sci 35(5):256–264PubMedCrossRefPubMedCentralGoogle Scholar
  42. 42.
    Nussinov R, Tsai CJ (2015) The design of covalent allosteric drugs. Annu Rev Pharmacol Toxicol 55:249–267PubMedCrossRefPubMedCentralGoogle Scholar
  43. 43.
    Nussinov R, Ma B, Tsai CJ, Csermely P (2013) Allosteric conformational barcodes direct signaling in the cell. Structure 21(9):1509–1521PubMedPubMedCentralCrossRefGoogle Scholar
  44. 44.
    Ostrem JM, Peters U, Sos ML, Wells JA, Shokat KM (2013) K-Ras (G12C) inhibitors allosterically control GTP affinity and effector interactions. Nature 503(7477):548–551PubMedPubMedCentralCrossRefGoogle Scholar
  45. 45.
    Perutz MF, Rossmann MG, Cullis AF, Muirhead H, Will G, North AC (1960) Structure of haemoglobin: a three-dimensional Fourier synthesis at 5.5-A. resolution, obtained by X-ray analysis. Nature 185(4711):416–422PubMedCrossRefPubMedCentralGoogle Scholar
  46. 46.
    Roy A, Kucukural A, Zhang Y (2010) I-TASSER: a unified platform for automated protein structure and function prediction. Nat Protoc 5(4):725–738PubMedPubMedCentralCrossRefGoogle Scholar
  47. 47.
    Schumacher MA, Zheleznova EE, Poundstone KS, Kluger R, Jones RT, Brennan RG (1997) Allosteric intermediates indicate R2 is the liganded hemoglobin end state. Proc Natl Acad Sci U S A 94(15):7841–7844PubMedPubMedCentralCrossRefGoogle Scholar
  48. 48.
    Seidel T, Ibis G, Bendix F, Wolber G (2010) Strategies for 3D pharmacophore-based virtual screening. Drug Discov Today Technol 7(4):e203–e270CrossRefGoogle Scholar
  49. 49.
    Shen Q, Wang G, Li S, Liu X, Lu S, Chen Z, Song K, Yan J, Geng L, Huang Z, Huang W, Chen G, Zhang J (2016) ASD v3.0: unraveling allosteric regulation with structural mechanisms and biological networks. Nucleic Acids Res 44(D1):D527–D535PubMedCrossRefPubMedCentralGoogle Scholar
  50. 50.
    Shibayama N, Sugiyama K, Tame JR, Park SY (2014) Capturing the hemoglobin allosteric transition in a single crystal form. J Am Chem Soc 136(13):5097–5105PubMedCrossRefPubMedCentralGoogle Scholar
  51. 51.
    Silva MM, Rogers PH, Arnone A (1992) A third quaternary structure of human hemoglobin A at 1.7-A resolution. J Biol Chem 267(24):17248–17256PubMedPubMedCentralGoogle Scholar
  52. 52.
    Smith RD, Lu J, Carlson HA (2017) Are there physicochemical differences between allosteric and competitive ligands? PLoS Comput Biol 13(11):e1005813PubMedPubMedCentralCrossRefGoogle Scholar
  53. 53.
    Tobi D (2016) Dynamics and allostery of the ionotropic glutamate receptors and the ligand binding domain. Proteins 84(2):267–277PubMedCrossRefPubMedCentralGoogle Scholar
  54. 54.
    van Westen GJ, Gaulton A, Overington JP (2014) Chemical, target, and bioactive properties of allosteric modulation. PLoS Comput Biol 10(4):e1003559PubMedPubMedCentralCrossRefGoogle Scholar
  55. 55.
    Wagner JR, Lee CT, Durrant JD, Malmstrom RD, Feher VA, Amaro RE (2016) Emerging computational methods for the rational discovery of allosteric drugs. Chem Rev 116(11):6370–6390PubMedPubMedCentralCrossRefGoogle Scholar
  56. 56.
    Wang Q, Zheng M, Huang Z, Liu X, Zhou H, Chen Y, Shi T, Zhang J (2012) Toward understanding the molecular basis for chemical allosteric modulator design. J Mol Graph Model 38:324–333PubMedCrossRefPubMedCentralGoogle Scholar
  57. 57.
    Wenthur CJ, Gentry PR, Mathews TP, Lindsley CW (2014) Drugs for allosteric sites on receptors. Annu Rev Pharmacol Toxicol 54:165–184PubMedCrossRefPubMedCentralGoogle Scholar
  58. 58.
    Williams G (2010) Elastic network model of allosteric regulation in protein kinase PDK1. BMC Struct Biol 10:11PubMedPubMedCentralCrossRefGoogle Scholar
  59. 59.
    Wootten D, Christopoulos A, Sexton PM (2013) Emerging paradigms in GPCR allostery: implications for drug discovery. Nat Rev Drug Discov 12(8):630–644PubMedCrossRefPubMedCentralGoogle Scholar
  60. 60.
    Wu H, Wang C, Gregory KJ, Han GW, Cho HP, Xia Y, Niswender CM, Katritch V, Meiler J, Cherezov V, Conn PJ, Stevens RC (2014) Structure of a class C GPCR metabotropic glutamate receptor 1 bound to an allosteric modulator. Science 344(6179):58–64PubMedPubMedCentralCrossRefGoogle Scholar
  61. 61.
    Yang SY (2010) Pharmacophore modeling and applications in drug discovery: challenges and recent advances. Drug Discov Today 15(11–12):444–450PubMedCrossRefPubMedCentralGoogle Scholar
  62. 62.
    Yelshanskaya MV, Li M, Sobolevsky AI (2014) Structure of an agonist-bound ionotropic glutamate receptor. Science 345(6200):1070–1074PubMedPubMedCentralCrossRefGoogle Scholar
  63. 63.
    Zhu S, Gouaux E (2017) Structure and symmetry inform gating principles of ionotropic glutamate receptors. Neuropharmacology 112(Pt A):11–15PubMedCrossRefPubMedCentralGoogle Scholar

Copyright information

© Springer Nature Singapore Pte Ltd. 2019

Authors and Affiliations

  • Kun Song
    • 1
  • Jian Zhang
    • 1
  • Shaoyong Lu
    • 1
  1. 1.Department of Pathophysiology, Key Laboratory of Cell Differentiation and Apoptosis of Chinese Ministry of EducationShanghai Jiao Tong University, School of MedicineShanghaiChina

Personalised recommendations